NOSTRAND ROBERT L VAN Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for NOSTRAND ROBERT L VAN.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of NOSTRAND ROBERT L VAN. NOSTRAND ROBERT L VAN is VP, & Chief Financial Officer in OSI PHARMACEUTICALS INC ($OSIP) and Director in METABOLIX, INC. ($MBLX) and in ACHILLION PHARMACEUTICALS INC ($ACHN) and Director in ACHILLION PHARMACEUTICALS INC ($ACHN) and Director in SELLAS Life Sciences Group, Inc. ($GALE) and Director in Enumeral Biomedical Holdings, Inc. ($ENUM) and Director in Intra-Cellular Therapies, Inc. ($ITCI).
Latest Insider Trading Transactions of NOSTRAND ROBERT L VAN
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, ACHN, ENUM, ITCI, OSIP, SLS, MBLX
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 26 2021 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 7.96 | 5,000 | 39,800 | 5,000 | |
| Apr 02 2021 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 33.93 | 208 | 7,057 | 8,273 | 8.1 K to 8.3 K (+2.58 %) |
| Apr 02 2021 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 12.54 | 383 | 4,803 | 383 | |
| Mar 08 2021 | SLS | SELLAS Life Scienc ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 8.00 | 7,500 | 60,000 | 7,500 | |
| Jan 04 2021 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 5.78 | 818 | 4,728 | 818 | |
| Jul 02 2020 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 25.67 | 275 | 7,059 | 7,567 | 7.3 K to 7.6 K (+3.77 %) |
| Jul 02 2020 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 6.26 | 777 | 4,864 | 777 | |
| May 29 2020 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 5.86 | 5,000 | 29,300 | 5,000 | |
| May 28 2020 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 22.02 | 20,000 | 440,400 | 20,000 | |
| Apr 02 2020 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 15.37 | 460 | 7,070 | 7,292 | 6.8 K to 7.3 K (+6.73 %) |
| Mar 16 2020 | SLS | SELLAS Life Scienc ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 1.89 | 6,500 | 12,285 | 6,500 | |
| Jan 29 2020 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Option Exercise | D | 2.18 | 42,000 | 91,560 | 0 | ||
| Jan 29 2020 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Option Exercise | D | 2.90 | 30,000 | 87,000 | 0 | ||
| Jan 29 2020 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Option Exercise | D | 3.02 | 25,000 | 75,500 | 0 | ||
| Jan 29 2020 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Option Exercise | D | 3.10 | 50,000 | 155,000 | 0 | ||
| Jan 29 2020 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Option Exercise | D | 4.09 | 30,000 | 122,700 | 0 | ||
| Jan 29 2020 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Option Exercise | D | 7.54 | 30,000 | 226,200 | 0 | ||
| Jan 29 2020 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Option Exercise | D | 7.59 | 20,000 | 151,800 | 0 | ||
| Jan 29 2020 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Sell | D | 6.30 | 40,000 | 252,000 | 0 | 40 K to 0 (-100.00 %) | |
| Jan 03 2020 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 34.31 | 170 | 5,833 | 6,832 | 6.7 K to 6.8 K (+2.55 %) |
| Jan 03 2020 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 34.31 | 170 | 5,833 | 6,832 | 6.7 K to 6.8 K (+2.55 %) |
| Dec 19 2019 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Option Exercise | M | 3.28 | 20,000 | 65,600 | 0 | ||
| Dec 19 2019 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Buy | M | 3.28 | 20,000 | 65,600 | 40,000 | 20 K to 40 K (+100.00 %) | |
| Oct 02 2019 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 0.50 | 9,845 | 4,923 | 9,845 | |
| Oct 02 2019 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 7.47 | 780 | 5,827 | 6,662 | 5.9 K to 6.7 K (+13.26 %) |
| Jul 02 2019 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 12.98 | 449 | 5,828 | 5,882 | 5.4 K to 5.9 K (+8.26 %) |
| Jul 02 2019 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 0.97 | 5,096 | 4,943 | 5,096 | |
| Jun 26 2019 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 13.05 | 20,000 | 261,000 | 20,000 | |
| May 23 2019 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 0.90 | 10,000 | 9,000 | 10,000 | |
| Apr 02 2019 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 12.18 | 478 | 5,822 | 5,433 | 5 K to 5.4 K (+9.65 %) |
| Apr 02 2019 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 1.14 | 4,321 | 4,926 | 4,321 | |
| Mar 18 2019 | SLS | SELLAS Life Scienc ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 1.38 | 25,000 | 34,500 | 25,000 | |
| Jan 25 2019 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 2.18 | 42,000 | 91,560 | 42,000 | |
| Jan 03 2019 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 11.39 | 512 | 5,832 | 4,955 | 4.4 K to 5 K (+11.52 %) |
| Jan 03 2019 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 0.83 | 5,924 | 4,917 | 5,924 | |
| Jan 03 2019 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 0.83 | 5,924 | 4,917 | 5,924 | |
| Dec 18 2018 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | M | 1.05 | 20,000 | 21,000 | 0 | |
| Dec 18 2018 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Director | Buy | M | 1.05 | 20,000 | 21,000 | 20,000 | 0 to 20 K |
| Oct 02 2018 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 21.70 | 268 | 5,816 | 4,443 | 4.2 K to 4.4 K (+6.42 %) |
| Oct 02 2018 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 1.44 | 3,396 | 4,890 | 3,396 | |
| Jul 03 2018 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 1.41 | 3,464 | 4,884 | 3,464 | |
| Jun 20 2018 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 20.39 | 20,000 | 407,800 | 20,000 | |
| Jun 20 2018 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 20.39 | 20,000 | 407,800 | 20,000 | |
| Jun 13 2018 | SLS | SELLAS Life Scienc ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 5.23 | 5,500 | 28,765 | 5,500 | |
| May 25 2018 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 1.65 | 10,000 | 16,500 | 10,000 | |
| Apr 02 2018 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 1.95 | 2,860 | 5,577 | 2,860 | |
| Mar 15 2018 | GALE | SELLAS Life Scienc ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 5.24 | 11,000 | 57,640 | 11,000 | |
| Jan 03 2018 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 1.77 | 13,003 | 23,015 | 13,003 | |
| Nov 30 2017 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 2.34 | 10,165 | 23,786 | 10,165 | |
| Oct 03 2017 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 316 | 0 | 3,311 | 3 K to 3.3 K (+10.55 %) |
| Jul 05 2017 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 3,519 | 0 | 11,293 | 7.8 K to 11.3 K (+45.27 %) |
| Jun 29 2017 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 12.45 | 20,000 | 249,000 | 20,000 | |
| May 26 2017 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 0.42 | 25,000 | 10,500 | 25,000 | |
| May 26 2017 | MBLX | YIELD10 BIOSCIENCE ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 43,155 | 0 | 46,488 | 3.3 K to 46.5 K (+1,294.78 %) |
| Jan 19 2017 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 4.09 | 30,000 | 122,700 | 30,000 | |
| Jan 05 2017 | ENUM | Enumeral Biomedica ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 66,666 | 0 | 268,121 | 201.5 K to 268.1 K (+33.09 %) |
| Jan 03 2017 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 331 | 0 | 2,286 | 2 K to 2.3 K (+16.93 %) |
| Dec 13 2016 | ENUM | Enumeral Biomedica ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | M | 0.50 | 156,000 | 78,000 | 0 | |
| Dec 13 2016 | ENUM | Enumeral Biomedica ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | J | 0.50 | 156,000 | 78,000 | 156,000 | |
| Dec 13 2016 | ENUM | Enumeral Biomedica ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | P | 2.00 | 39,000 | 78,000 | 39,000 | |
| Dec 13 2016 | ENUM | Enumeral Biomedica ... | VAN NOSTRAND ROBERT L | Director | Buy | M | 0.13 | 156,000 | 19,500 | 201,455 | 45.5 K to 201.5 K (+343.20 %) |
| Oct 04 2016 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 328 | 0 | 1,955 | 1.6 K to 2 K (+20.16 %) |
| Jul 05 2016 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 128 | 0 | 1,627 | 1.5 K to 1.6 K (+8.54 %) |
| Jun 15 2016 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 38.35 | 20,000 | 767,000 | 20,000 | |
| Apr 04 2016 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 134 | 0 | 1,499 | 1.4 K to 1.5 K (+9.82 %) |
| Jan 27 2016 | ACHN | ACHILLION PHARMACE ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 7.54 | 30,000 | 226,200 | 30,000 | |
| Jan 06 2016 | ENUM | Enumeral Biomedica ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 45,455 | 0 | 45,455 | 0 to 45.5 K |
| Jan 05 2016 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 53.79 | 69 | 3,712 | 1,365 | 1.3 K to 1.4 K (+5.32 %) |
| Oct 02 2015 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 93 | 0 | 1,296 | 1.2 K to 1.3 K (+7.73 %) |
| Sep 24 2015 | ENUM | Enumeral Biomedica ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 0.47 | 76,000 | 35,720 | 76,000 | |
| Sep 14 2015 | MBLX | METABOLIX, INC. | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 31,250 | 0 | 31,250 | 0 to 31.3 K |
| Jul 02 2015 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 117 | 0 | 1,203 | 1.1 K to 1.2 K (+10.77 %) |
| Jun 22 2015 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Option Exercise | A | 26.58 | 20,000 | 531,600 | 20,000 | |
| Apr 02 2015 | ITCI | Intra-Cellular The ... | VAN NOSTRAND ROBERT L | Director | Grant | A | 0.00 | 157 | 0 | 1,086 | 929 to 1.1 K (+16.90 %) |
| May 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Option Exercise | M | 21.55 | 1,250 | 26,938 | 8,955 | |
| May 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 47.50 | 300 | 14,250 | 4,899 | 5.2 K to 4.9 K (-5.77 %) |
| May 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 47.49 | 200 | 9,498 | 5,199 | 5.4 K to 5.2 K (-3.70 %) |
| May 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 47.42 | 200 | 9,484 | 5,399 | 5.6 K to 5.4 K (-3.57 %) |
| May 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 47.41 | 100 | 4,741 | 5,599 | 5.7 K to 5.6 K (-1.75 %) |
| May 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 47.39 | 300 | 14,217 | 5,699 | 6 K to 5.7 K (-5.00 %) |
| May 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 47.38 | 150 | 7,107 | 5,999 | 6.1 K to 6 K (-2.44 %) |
| May 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Buy | M | 21.55 | 1,250 | 26,938 | 6,149 | 4.9 K to 6.1 K (+25.52 %) |
| Apr 19 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Option Exercise | M | 21.55 | 1,000 | 21,550 | 10,205 | |
| Apr 19 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 50.00 | 1,000 | 50,000 | 4,899 | 5.9 K to 4.9 K (-16.95 %) |
| Apr 19 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Buy | M | 21.55 | 1,000 | 21,550 | 5,899 | 4.9 K to 5.9 K (+20.41 %) |
| Apr 07 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Option Exercise | M | 21.55 | 1,250 | 26,938 | 11,205 | |
| Apr 07 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 45.00 | 1,250 | 56,250 | 4,899 | 6.1 K to 4.9 K (-20.33 %) |
| Apr 07 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Buy | M | 21.55 | 1,250 | 26,938 | 6,149 | 4.9 K to 6.1 K (+25.52 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Option Exercise | M | 21.55 | 2,250 | 48,488 | 12,455 | |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 54.70 | 28 | 1,532 | 4,899 | 4.9 K to 4.9 K (-0.57 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 54.50 | 16 | 872 | 4,927 | 4.9 K to 4.9 K (-0.32 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 54.31 | 16 | 869 | 4,943 | 5 K to 4.9 K (-0.32 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 54.30 | 31 | 1,683 | 4,959 | 5 K to 5 K (-0.62 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 54.12 | 127 | 6,873 | 4,990 | 5.1 K to 5 K (-2.48 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 54.11 | 16 | 866 | 5,117 | 5.1 K to 5.1 K (-0.31 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 54.10 | 607 | 32,839 | 5,133 | 5.7 K to 5.1 K (-10.57 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 54.05 | 106 | 5,729 | 5,740 | 5.8 K to 5.7 K (-1.81 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 54.02 | 16 | 864 | 5,846 | 5.9 K to 5.8 K (-0.27 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 54.01 | 48 | 2,592 | 5,862 | 5.9 K to 5.9 K (-0.81 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 54.00 | 207 | 11,178 | 5,910 | 6.1 K to 5.9 K (-3.38 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 53.94 | 119 | 6,419 | 6,117 | 6.2 K to 6.1 K (-1.91 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 53.91 | 16 | 863 | 6,236 | 6.3 K to 6.2 K (-0.26 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 53.86 | 32 | 1,724 | 6,252 | 6.3 K to 6.3 K (-0.51 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 53.84 | 318 | 17,121 | 6,284 | 6.6 K to 6.3 K (-4.82 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 53.83 | 347 | 18,679 | 6,602 | 6.9 K to 6.6 K (-4.99 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 53.82 | 64 | 3,444 | 6,949 | 7 K to 6.9 K (-0.91 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 53.81 | 16 | 861 | 7,013 | 7 K to 7 K (-0.23 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 53.80 | 32 | 1,722 | 7,029 | 7.1 K to 7 K (-0.45 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 53.76 | 88 | 4,731 | 7,061 | 7.1 K to 7.1 K (-1.23 %) |
| Mar 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Buy | M | 21.55 | 2,250 | 48,488 | 7,149 | 4.9 K to 7.1 K (+45.93 %) |
| Feb 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Option Exercise | M | 21.55 | 2,095 | 45,147 | 14,705 | |
| Feb 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Option Exercise | M | 7.09 | 155 | 1,100 | 0 | |
| Feb 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 65.16 | 1,044 | 68,027 | 4,899 | 5.9 K to 4.9 K (-17.57 %) |
| Feb 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 65.15 | 301 | 19,610 | 5,943 | 6.2 K to 5.9 K (-4.82 %) |
| Feb 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 65.10 | 604 | 39,320 | 6,244 | 6.8 K to 6.2 K (-8.82 %) |
| Feb 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 65.00 | 301 | 19,565 | 6,848 | 7.1 K to 6.8 K (-4.21 %) |
| Feb 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Buy | M | 21.55 | 2,095 | 45,147 | 7,149 | 5.1 K to 7.1 K (+41.45 %) |
| Feb 03 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Buy | M | 7.09 | 155 | 1,100 | 5,054 | 4.9 K to 5.1 K (+3.16 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Option Exercise | M | 7.09 | 5,500 | 39,017 | 155 | |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 74.60 | 28 | 2,089 | 4,899 | 4.9 K to 4.9 K (-0.57 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 74.50 | 138 | 10,281 | 4,927 | 5.1 K to 4.9 K (-2.72 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 74.47 | 1,805 | 134,418 | 5,065 | 6.9 K to 5.1 K (-26.27 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 74.43 | 14 | 1,042 | 6,870 | 6.9 K to 6.9 K (-0.20 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 74.42 | 96 | 7,144 | 6,884 | 7 K to 6.9 K (-1.38 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 74.41 | 69 | 5,134 | 6,980 | 7 K to 7 K (-0.98 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 74.40 | 81 | 6,026 | 7,049 | 7.1 K to 7 K (-1.14 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 74.17 | 14 | 1,038 | 7,130 | 7.1 K to 7.1 K (-0.20 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 74.10 | 28 | 2,075 | 7,144 | 7.2 K to 7.1 K (-0.39 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 74.05 | 110 | 8,146 | 7,172 | 7.3 K to 7.2 K (-1.51 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 73.95 | 345 | 25,513 | 7,282 | 7.6 K to 7.3 K (-4.52 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 73.65 | 689 | 50,745 | 7,627 | 8.3 K to 7.6 K (-8.29 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 73.62 | 14 | 1,031 | 8,316 | 8.3 K to 8.3 K (-0.17 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 73.60 | 41 | 3,018 | 8,330 | 8.4 K to 8.3 K (-0.49 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 73.53 | 1,408 | 103,530 | 8,371 | 9.8 K to 8.4 K (-14.40 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 73.52 | 620 | 45,582 | 9,779 | 10.4 K to 9.8 K (-5.96 %) |
| Jan 05 2005 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Buy | M | 7.09 | 5,500 | 39,017 | 10,399 | 4.9 K to 10.4 K (+112.27 %) |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Option Exercise | M | 7.09 | 2,750 | 19,509 | 5,655 | |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 48.74 | 16 | 780 | 4,899 | 4.9 K to 4.9 K (-0.33 %) |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 48.66 | 78 | 3,795 | 4,915 | 5 K to 4.9 K (-1.56 %) |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 48.65 | 280 | 13,622 | 4,993 | 5.3 K to 5 K (-5.31 %) |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 48.64 | 16 | 778 | 5,273 | 5.3 K to 5.3 K (-0.30 %) |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 48.60 | 15 | 729 | 5,289 | 5.3 K to 5.3 K (-0.28 %) |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 48.58 | 156 | 7,578 | 5,304 | 5.5 K to 5.3 K (-2.86 %) |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 48.57 | 280 | 13,600 | 5,260 | 5.5 K to 5.3 K (-5.05 %) |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 48.50 | 341 | 16,539 | 5,740 | 6.1 K to 5.7 K (-5.61 %) |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 48.45 | 16 | 775 | 6,081 | 6.1 K to 6.1 K (-0.26 %) |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 48.41 | 31 | 1,501 | 6,097 | 6.1 K to 6.1 K (-0.51 %) |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 48.40 | 140 | 6,776 | 6,128 | 6.3 K to 6.1 K (-2.23 %) |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 48.37 | 264 | 12,770 | 6,268 | 6.5 K to 6.3 K (-4.04 %) |
| Dec 03 2004 | OSIP | OSI PHARMACEUTICAL ... | VAN NOSTRAND ROBERT L | VP, & Chief Financi ... | Sell | S | 48.29 | 121 | 5,843 | 6,532 | 6.7 K to 6.5 K (-1.82 %) |